NIH AIDS Reagent Program
20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent:	BF24 Cells
Catalog Number:	1296
Lot Number:	97136
Release Category:	C
Provided:	6 x 10^6 cells/vial.
Propagation Medium:	RPMI 1640, 90%; fetal bovine serum, 10%.
Freeze Medium:	RPMI 1640, 70%; fetal bovine serum, 20%; DMSO, 10%.
Growth Characteristics:	Split twice weekly 1:3. BF24 cells are stable and do not need to be maintained in selection medium. If growth in selection medium is desired, propagation medium containing 700 µg/ml G418 should be used. Wash the thawed cells in propagation medium and centrifuge for 10 minutes at 1000 rpm before seeding the cells in a culture flask.
Sterility:	Negative for bacteria, fungi, and mycoplasma.
Description:	BF24 cells are a THP-1 derivative that contains stably integrated, silent copies of the HIV-1 LTR promoter linked to the CAT gene.
Special Characteristics:	This cell line was generated by infection of THP-1 cells with a helper-free recombinant retroviral vector containing the HIV-1 LTR-CAT gene construct. BF24 was selected in geneticin (G418) under limiting dilution and is a sensitive indicator cell line for HIV-1 Tat. When infected by HIV-1, BF24 produces high levels of chloramphenicol acetyl transferase (CAT)[1,2]. Contains LTR sequences to +80 in the R region. Contains the entire U3 region, but lacks U5 sequences.
Recommended Storage:	Liquid nitrogen.

Contributor: Dr. Barbara K. Felber and Dr. George N. Pavlakis.

References:

[1]Schwartz S, Felber BK, Fenyo EM, Pavlakis, GN. Rapidly and slowly replicating human immunodeficiency virus type 1 isolates can be distinguished according to target-cell tropism in T-cell and monocyte cell lines. *Proc Natl Acad Sci USA* **86**:7200-7203, 1989.

[2]Felber BK, Pavlakis G.. A quantitative bioassay for HIV-1 based on trans-activation. *Science* **239**:184-187, 1988.

NOTE: Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: BF24 Cells from Dr. Barbara K. Felber and Dr. George N. Pavlakis." Also include the references cited above in any publications.

An NCI patent application has been filed on the use of the cell line H938. Corporate requests should be directed in writing to: B.K. Felber or G.N. Pavlakis, National Cancer Institute, FCRDC, ABL-Basic Research Program, P.O. Box B/Building 539, Room 121, Frederick, Maryland 21702-1201. Phone: (301) 846-1474, FAX (301) 846-5991.

Last Updated July 02, 2018